Indian multinational pharmaceutical company making branded and generic medicines and APIs, sold in 80+ countries.
cipla.comFounded
1935Headquarters
Mumbai, Maharashtra, India
Industry
Pharmaceuticals
Employees
27,764 (March 2024)
Revenue (FY26)
Approx ₹28,163 crore (consolidated)Market Cap
Approx ₹1,14,148 crore (July 2026)
Listed on
NSE: CIPLA / BSE: 500087 (NIFTY 50)
Global CEO
Achin Gupta (from 1 April 2026)
Chairman
Dr. Y. K. Hamied
Global CFO
Ashish Adukia
Cipla Limited is an Indian multinational pharmaceutical company founded in 1935 and headquartered in Mumbai. It develops, manufactures, and markets branded and generic formulations along with active pharmaceutical ingredients. It ranks among India's largest drug makers, with products sold in more than 80 countries and roughly 47 manufacturing sites worldwide.
The company is listed on the NSE (CIPLA) and BSE (500087) and sits in the NIFTY 50 index. For fiscal year 2026 it reported consolidated revenue of about ₹28,163 crore, up from ₹27,548 crore in FY2025, and its market capitalization stood near ₹1,14,148 crore in July 2026. India contributed roughly 45% of FY26 revenue, with North America and emerging markets making up much of the balance.
Cipla went through a planned leadership change in 2026. Achin Gupta became Managing Director and Global CEO on 1 April 2026, succeeding Umang Vohra, who had led the company for about a decade. Dr. Y. K. Hamied continues as Non-Executive Chairman, Ashish Adukia serves as Global CFO, and Arun Kakatkar joined as Global Chief People Officer in March 2026.
Managing Director & Global CEO (effective 1 April 2026)
Non-Executive Chairman
Global Chief Financial Officer
Global Chief People Officer (effective 17 March 2026)
Interview experience
7 out of 10
Interview difficulty
Medium
Interview process length
Around a week
Practice real questions and get instant feedback before the real thing.
Q: Basic knowledge of chemistry and instruments.
A: Interviewers want to see that you understand core chemistry concepts and can name the lab instruments a QC role uses day to day. Keep answers concrete and tie each concept to a real lab task.
Q: What is your qualification? (B.Sc Chemistry related questions)
A: Walk through your degree, key subjects, and any lab or dispensing experience, then connect them to the pharmacist role. Be ready for follow-up chemistry questions tied to your coursework.
Q: Can you work under pressure?
A: This is a behavioural question, so give a short real example using a simple structure. Describe a deadline or high-stakes situation, what you did, and the outcome.
Q: Questions about my past experiences and legal knowledge.
A: Prepare a tight summary of your career and the domains you know well, including any compliance or regulatory exposure relevant to pharma. Match each point to what the role needs.
Practice real questions and get instant feedback before the real thing.
Estimated average
₹14,89,211/yr
9 salaries Salaries submitted
Estimated average
₹5,07,091/yr
8 salaries Salaries submitted
Estimated average
₹11,29,203/yr
5 salaries Salaries submitted
Average with band
₹23,63,387/yr (band ₹22,09,146 to ₹25,28,398)
3 salaries Salaries submitted
Estimated average
₹13,12,976/yr
3 salaries Salaries submitted
Estimated average
₹13,98,281/yr
3 salaries Salaries submitted
See how your target salary compares and find roles that match it.
Mumbai, Maharashtra • Full-time
Mumbai, Maharashtra • Full-time
Mumbai, Maharashtra • Full-time
Mumbai, Maharashtra • Full-time
Bengaluru, Karnataka • Full-time
Rangpo, Sikkim • Full-time
Tailor your resume to Cipla roles and get past the first screen.
July 20, 2026
USFDA issues one Form 483 observation to Cipla's InvaGen plant
A routine cGMP inspection of Cipla subsidiary InvaGen Pharmaceuticals' Central Islip facility in New York, held July 13 to 17, 2026, closed with a single Form 483 observation. Cipla said it will address the observation within the required timeframe.
#USFDA #InvaGen #Compliance
View postJuly 6, 2026
Cipla posts highest-ever FY26 revenue of about 28,000 crore rupees
Cipla reported record FY26 revenue near 28,000 crore rupees with a 21% EBITDA margin, and its India business crossed 12,500 crore rupees for the first time at 9% year-on-year growth. Cash reserves rose to about 11,000 crore rupees.
#FY26Results #Earnings #IndiaBusiness
View postJuly 1, 2026
Cipla sets July 23 board meeting for Q1FY27 results
Cipla scheduled its board meeting for July 23, 2026, to review unaudited Q1FY27 results, targeting a US generic run-rate of about 250 million dollars per quarter. It also flagged Voluntary Action Indicated status for its Pithampur Unit 1.
#Q1FY27 #Earnings #USGenerics
View postJune 10, 2026
Cipla convenes 90th AGM on June 25 with 13 rupee final dividend
Cipla confirmed its 90th AGM for June 25, 2026 and a recommended final FY26 dividend of 13 rupees per share, with a record date of June 5, 2026. The company also corrected its remote e-voting end date to June 24.
#Dividend #AGM #Shareholders
View postApril 24, 2026
Cipla wins USFDA approval for Albuterol Sulfate Inhalation Aerosol
Cipla received final USFDA approval for Albuterol Sulfate Inhalation Aerosol, a therapeutic equivalent of GSK's Ventolin HFA, for a US market worth about 1.5 billion dollars. The company plans a US launch in the first half of FY27.
#USFDA #Respiratory #ProductLaunch
View postCipla was founded in 1935 and is headquartered at Cipla House, Peninsula Business Park, Lower Parel, Mumbai, Maharashtra, India.
